Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy

Mengchao An(Zhengzhou University), Zibing Wang(Zhengzhou University), Hong Cui(Chinese Academy of Medical Sciences & Peking Union Medical College), Quanli Gao(Zhengzhou University), Brian G. Till(University of Washington), Yunjian Wang(Zhengzhou University), Tiepeng Li(Zhengzhou University), Lingdi Zhao(Zhengzhou University), Yonghao Yang(Zhengzhou University), Min Zhang(Zhengzhou University), Jie Zhang(Fudan University), Xiaojie Zhang(Gyeongsang National University), Hao Huang(Zhengzhou University), Lu Han(Nanjing Jiangning Hospital), Wenkang Wang(ZheJiang Institute For Food and Drug Control)
Cancer Immunology Immunotherapy
July 30, 2022
10.1007/s00262-022-03254-w
Cited by 19

Related Papers

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
|Blood|2008|719
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
|Blood|2012|530
Breakthrough of solid tumor treatment: CAR-NK immunotherapy
|Cell Death Discovery|2024|145
Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
|Cell Death and Disease|2023|130
Intensive Care Unit-Acquired Weakness: A Review of Recent Progress With a Look Toward the Future
|Frontiers in Medicine|2020|117